465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

Home・Akciju saraksts・Gimv NV

Gimv NV

Slēgts

SektorsFinanšu

43.35 -0.69

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

42.3

Max

44.05

Galvenie mērījumi
By Trading Economics
Ienākumi	127M
Pārdošana	-49M 65M
P/E Sektora vidējais	7.675 54.048
EPS	3.4
Dividenžu ienesīgums	10
Peļņas marža	195.239
Darbinieki	94
EBITDA	52M 128M

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	10.00% 4.84%
Nākamie ieņēmumi	2026. g. 21. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	46M 1.7B
Iepriekšējā atvēršanas cena	44.04
Iepriekšējā slēgšanas cena	43.35

Ziņu noskaņojums

By Acuity

50%

160 / 441 Rangs Finance

Gimv NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. marts 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026. g. 23. marts 22:55 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026. g. 23. marts 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026. g. 23. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026. g. 23. marts 23:37 UTC

Tirgus saruna

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna

Galvenie ziņu notikumi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026. g. 23. marts 22:40 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026. g. 23. marts 22:23 UTC

Tirgus saruna

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026. g. 23. marts 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026. g. 23. marts 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026. g. 23. marts 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026. g. 23. marts 22:08 UTC

Tirgus saruna

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026. g. 23. marts 21:10 UTC

Galvenie ziņu notikumi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Peļņas

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Gimv NV Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Gimv NV — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

160 / 441 Rangs Finanšu

Finanšu rādītāji

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Gimv NV

Gimv NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, later stage, mature, replacement capital, bridge financing, and recapitalization. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer, connected consumer, fintech; health and care; smart industries; and sustainable cities. Within consumer, it seeks to provide growth capital to emerging leaders. Within health and care platform, the firm seeks to invest in companies that can grow either organically or through a buy and build strategy. Within consumer, it focuses on consumer goods, food and beverage, healthy food, sport, convenience food, personal luxury, career, home & deco, baby & kids, pet products, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. Within health and care sector, it focuses on life sciences, medtech, and health and care services. The firm focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as medical devices, consumables, IT and small equipment, and health and care services-based companies. It also seeks to be an active shareholder, preferably lead or co-lead in its investments. Within smart industries, it focuses on equipment, services and tools for resource efficient development and production, automotive and aerospace, both optimizing of the existing and development of new means of transport, software and services harnessing the flexibility of the cloud, smart data management and advanced c